NZ332879A - Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes - Google Patents

Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes

Info

Publication number
NZ332879A
NZ332879A NZ332879A NZ33287997A NZ332879A NZ 332879 A NZ332879 A NZ 332879A NZ 332879 A NZ332879 A NZ 332879A NZ 33287997 A NZ33287997 A NZ 33287997A NZ 332879 A NZ332879 A NZ 332879A
Authority
NZ
New Zealand
Prior art keywords
leptin
diabetes
protein
fragments
treating obesity
Prior art date
Application number
NZ332879A
Other languages
English (en)
Inventor
Kamal A Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NZ332879A publication Critical patent/NZ332879A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NZ332879A 1996-06-06 1997-06-04 Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes NZ332879A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds
PCT/EP1997/002968 WO1997046585A2 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)

Publications (1)

Publication Number Publication Date
NZ332879A true NZ332879A (en) 2000-09-29

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332879A NZ332879A (en) 1996-06-06 1997-06-04 Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes

Country Status (15)

Country Link
EP (1) EP0912609A2 (fr)
JP (1) JP2000512137A (fr)
KR (1) KR20000016402A (fr)
CN (1) CN1221426A (fr)
AR (1) AR008765A1 (fr)
AU (1) AU3337297A (fr)
BR (1) BR9709529A (fr)
CA (1) CA2257240A1 (fr)
CZ (1) CZ397898A3 (fr)
IL (1) IL127153A0 (fr)
NO (1) NO985683L (fr)
NZ (1) NZ332879A (fr)
PL (1) PL330361A1 (fr)
TR (1) TR199802534T2 (fr)
WO (1) WO1997046585A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335107C (fr) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Induction de genes a mediation par la leptine
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2001021647A2 (fr) * 1999-09-22 2001-03-29 Genset Procedes de criblage de composes qui modulent l'interaction de la lsr-leptine et utilisations de ces composes dans la prevention et le traitement des maladies liees a l'obesite
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
WO2003034996A2 (fr) 2001-10-22 2003-05-01 Amgen, Inc. Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
CA2535021A1 (fr) 2003-09-08 2005-03-17 Applied Research Systems Ars Holding N.V. Utilisation de l'insp035 dans le traitement de maladies fibreuses
EP2417980A1 (fr) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
EP1812038A1 (fr) 2004-11-18 2007-08-01 VIB vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
CA2597649A1 (fr) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
CA2707555A1 (fr) 2007-12-05 2009-06-11 Astrazeneca Ab Piperazines comme agents anti-obesite
ATE546441T1 (de) 2007-12-05 2012-03-15 Astrazeneca Ab Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors
JP2011522007A (ja) * 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ レプチン受容体修飾因子模倣剤としての新しいピリジン誘導体
CA2725949A1 (fr) * 2008-06-04 2009-12-10 Astrazeneca Ab Nouveaux composes v
WO2010118384A2 (fr) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Composés agonistes de l'amyline pour mammifères ayant une carence en oestrogènes
EP2569326B1 (fr) * 2010-05-11 2016-08-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibiteur peptidique de la signalisation de l'interleukine-10 ou de l'activation de stat-3
WO2012050925A2 (fr) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Leptines hautement solubles
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
EP0912609A2 (fr) 1999-05-06
AR008765A1 (es) 2000-02-23
IL127153A0 (en) 1999-09-22
JP2000512137A (ja) 2000-09-19
PL330361A1 (en) 1999-05-10
BR9709529A (pt) 1999-08-10
AU3337297A (en) 1998-01-05
WO1997046585A2 (fr) 1997-12-11
CZ397898A3 (cs) 1999-04-14
NO985683D0 (no) 1998-12-04
CN1221426A (zh) 1999-06-30
NO985683L (no) 1998-12-04
WO1997046585A3 (fr) 1998-04-23
CA2257240A1 (fr) 1997-12-11
KR20000016402A (ko) 2000-03-25
TR199802534T2 (xx) 1999-03-22

Similar Documents

Publication Publication Date Title
NZ332879A (en) Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
GB2292382B (en) Obesity (OB) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vect
EP1231218A3 (fr) Peptide coupe-faim, ses compositions et son utilisation
HK1013094A1 (en) Aldehyde-cured proteinaceous adhesive
NO992557D0 (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
MY132189A (en) Recombinant obese (ob) proteins
NO995044D0 (no) Osteoprotegerinbindende proteiner og reseptorer
EP1194164B8 (fr) Peptides proteiniques du prion et utilisations associees
DK0881906T4 (da) Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser
EP1077217A3 (fr) Peptides neuroactives et leur utilisation
SE9603533L (sv) Specifika peptider för behandling av diabetes mellitus
SG63615A1 (en) Dna encoding a human calcium channel alpha-ie subunit
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU2002216551A1 (en) Activity control during dieting
CA2268796A1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
DK0990703T3 (da) Nyt polypeptid, DNA, som koder herfor, samt anvendelse heraf
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
AU1879097A (en) Fragments of cr1 and their use
AU2344995A (en) Peptide fragments and analogs derived from PBAN 1-33 NH2 for controlling moths
DE69733026D1 (de) Cyclin e spezifische konstrukte und komplexe
AU6723898A (en) Composition for treating tanned leather, and its preparation
AU7145891A (en) Nailing system for treating fractures, particularly cervico-trochanterian and pertrochanterian fractures
AU6977994A (en) Peptides derived from human interleukin-2 for use in medicine
AU8744691A (en) N-((2-thenoylmercapto-3-methyl)-butanoyl)-homocysteine thiolactone, a process for the preparation thereof and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired